Oncotarget

Research Papers:

Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review

Hao Guo, Shuni Zhou, Lili Tan, Xiaoyu Wu, Zhenfeng Wu and Ruizhi Ran _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:2550-2557. https://doi.org/10.18632/oncotarget.13707

Metrics: PDF 1786 views  |   HTML 2324 views  |   ?  


Abstract

Hao Guo1,*, Shuni Zhou2,*, Lili Tan1, Xiaoyu Wu3, Zhenfeng Wu3, Ruizhi Ran1

1Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefacture, Enshi, Hubei 445000, China

2Department of Chinese Medicine and Cardiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefacture, Enshi, Hubei 445000, China

3Surgical Oncology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, 1 Nanjing 210029, China

*These authors contributed equally to this work

Correspondence to:

Ruizhi Ran, email: [email protected]

Keywords: NSCLC, WIF-1, methylation, tumor suppressor gene, drug target

Received: September 12, 2016     Accepted: November 15, 2016     Published: November 29, 2016

ABSTRACT

Methylation of the WIF-1 gene can lead to the loss of WIF-1 expression which has been observed in numerous types of cancer including NSCLC. However, the association and clinicopathological significance between WIF-1 promoter hypermethylation and NSCLC remains unclear. In the present study, we performed a meta-analysis to evaluate the clinicopathological significance of WIF-1 hypermethylation in NSCLC. A systematic literature search was carried out using Pubmed, EMBASE, Web of Science and CNKI. The Cochrane software Review manager 5.2 was used. The frequency of WIF-1 hypermethylation was significantly increased in NSCLC compared with normal lung tissue; the pooled OR was 8.67 with 95% CI 1.64-45.88, p = 0.01. The rate of WIF-1 hypermethylation was higher in SCC than in AC, OR was 1.74 with 95% CI 0.97-3.11, p = 0.06. In addition, WIF-1 loss was correlated with low 5-year survival rate. In summary, WIF-1 hypermethylation is a potential biomarker for diagnosis of NSCLC. WIF-1 hypermethylation is predominant in squamous cell carcinoma (SCC), suggesting that WIF-1 methylation contributes to the development of NSCLC, especially SCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13707